



Technical Report No. 83

Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response

PDA Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response Technical Report Team

Authors and Contributors

Houman Dehghani, Ph.D., Allogene Therapeutics (Co-Lead)

Robert Kiss, Ph.D., Sutro Biopharma (Co-Lead)

Marshall Dinowitz, Sc.D., Pacific BioDevelopment (Retired)

Jim Gilbert, Ph.D., Consultant

Linda Hendricks, Johnson & Johnson

Rajesh Krishnan, Ph.D., Oncernal Therapeutics

Yuling Li, Ph.D., Apollomics Inc.

Mark Lutgen, KBI Biopharma

Eric Mundhenke, KBI Biopharma

Anne Stokes, Ph.D., GlaxoSmithKline PLC

Dominick Vacante, Ph.D., Janssen R&D, LLC

Michael Wiebe, Ph.D., Quantum Consulting, LLC

To order this document, please visit: go.pda.org/TR83

Virus Contamination in Biomanufacturing: Risk Mitigation, Preparedness, and Response

Technical Report No. 83

ISBN: 978-1-945584-10-7

© 2019 Parenteral Drug Association, Inc.

All rights reserved.



www.pda.org/store

Table of Contents

1.0 INTRODUCTION	1	4.0 PREPARATION FOR A VIRUS CONTAMINATION ..	18
1.1 Purpose.....	1	4.1 Virus Contamination Response Plan	18
1.2 Scope	2	4.2 Investigation Management Structure and Leadership	19
2.0 GLOSSARY	2	4.3 Response Plan Elements.....	19
2.1 Abbreviations.....	3	5.0 RESPONSE TO A VIRUS CONTAMINATION.....	24
3.0 RISK MITIGATION.....	3	5.1 Detection of Contamination	24
3.1 Risk Analysis and Management.....	3	5.1.1 Cell Substrate	25
3.1.1 Raw Materials.....	4	5.1.2 Raw Materials.....	25
3.1.2 Assessment of High-Risk Raw Materials	4	5.1.3 Cell Culture Process.....	25
3.1.3 Replacement of High-Risk Materials.....	5	5.2 Identification of Contaminant	26
3.1.4 Control of the Raw Material Source.....	5	5.3 Containment, Inactivation and Decontamination	26
3.1.5 Cell Substrate.....	7	5.3.1 Components of Facility Decontamination and Cleanup	27
3.1.6 Facility.....	8	5.4 Root Cause Analysis, Corrective & Preventive Actions, and Facility Restart	29
3.1.7 Use of a Risk Management Tool	8	5.5 Product and Supply Impact.....	30
3.1.8 Example of Risk Assessment of mAb Produced by CHO Cells.....	9	6.0 CONCLUSIONS.....	31
3.2 Mitigation	12	7.0 REFERENCES.....	31
3.2.1 Facility and Equipment Considerations	12		
3.2.2 Operational Practices.....	14		
3.3 Barriers to Contamination in the Cell Culture Processing Areas.....	15		
3.3.1 Treatment of High-Risk Raw Materials	15		
3.3.2 Testing of Cell Banks and Raw Materials	16		
3.3.3 Development and Qualification of Robust, State-of-the-Art Methodologies for In-Process Viral Testing	17		

FIGURES AND TABLES INDEX

Figure 1.1-1	Virus Contamination Risk Management Approach.....	Table 3.1.8-3	Worked Example for Initial Risk Evaluation
	1		10
Table 3.1.8-1	Scoring System for Probability and Impact (Severity) of Risk	Table 3.1.8-4	Example of a Portion of a Risk Assessment for Manufacturing Facility
	9		11
Table 3.1.8-2	Guideline (Grid) for Probability and Impact of Risk.....	Table 4.3-1	Contamination Response Plan Elements
	10		20



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org